Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy. - Wikidata - wikimedia - TriplyDB

Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.

Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.

http://www.wikidata.org/entity/Q34803707

about

Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect Adoptive T-cell therapy for Leukemia Immunotherapy: opportunities, risks and future perspectives Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma.The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.Recent advances in T-cell immunotherapy for haematological malignancies.Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.An adjuvanted whole cell vaccine as post-remission immunotherapy for acute leukemia.Antigen-specific culture of memory-like CD8 T cells for adoptive immunotherapy.Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.

P2860

Q26770391-66938B96-60D4-4D0D-A5F8-593125046F82 Q26775720-4FF19AB5-2060-4117-88B7-03DEE4F8DF71 Q26826830-743D7033-F4ED-4F4B-BA2F-3C99DAA2B40C Q27006934-30099352-C191-45DF-BC45-80E4D57B48CC Q33941012-9A869C15-5E8D-4288-B686-1B90087E7A2B Q35591430-40A00132-8287-4405-A4EE-43593B638207 Q35623772-E4E8E53A-37A5-417E-BC26-298DCC418083 Q36772346-0B8DE7DE-0BF8-4446-8BFB-B14859AAB473 Q37242561-B92105B5-B8A1-4463-8FD8-7F9DB84A134B Q37707135-50A7EE7D-0527-47C7-A6E5-B1651BC68347 Q38693404-C79E648D-0BD0-47E8-8745-2CCA3BC3640E Q38719407-96A30A8A-42EA-483C-8B74-883978BE5D3C Q38789518-68E8C63B-C260-47DB-A403-C74C8A908792 Q38947206-9B6C772A-6C8F-4EA8-A290-F96CE0785B0D Q39243052-5BB0802D-6AF0-432A-B997-22D7A148ECF1 Q40657274-1C371A1B-D78E-4095-B8E6-BD1F6155E3B8 Q41593302-44FB1CD8-4CC4-46F1-8848-F9074EABBE0E Q42124330-7610CB02-1FF7-4DB3-8F6A-5451F5ACDD01 Q47289766-21B99948-5654-4E8C-A26A-0E7BBEF8C669 Q53643579-856417EE-F932-419A-805F-9EAE8EE9D9FE Q55216432-6163BD1F-A599-43B8-AE34-2273C7ADC7D4

P2860

Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.

http://www.wikidata.org/entity/Q34803707

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Generation of tumor antigen-sp ...... mplications for immunotherapy.

@ast

Generation of tumor antigen-sp ...... mplications for immunotherapy.

@en

Generation of tumor antigen-sp ...... mplications for immunotherapy.

@nl

type

label

Generation of tumor antigen-sp ...... mplications for immunotherapy.

@ast

Generation of tumor antigen-sp ...... mplications for immunotherapy.

@en

Generation of tumor antigen-sp ...... mplications for immunotherapy.

@nl

prefLabel

Generation of tumor antigen-sp ...... mplications for immunotherapy.

@ast

Generation of tumor antigen-sp ...... mplications for immunotherapy.

@en

Generation of tumor antigen-sp ...... mplications for immunotherapy.

@nl

P1433

Q34803707-0B71A69A-7B15-4354-A7BB-B2370FEF35A8

P1476

Q34803707-BF83E173-D366-4BB6-BF02-5BBD3A905607

P2093

Q34803707-27654A04-D9AD-4DF5-9AB3-09829F4C95F9

Q34803707-3C0D331B-5155-4570-931D-8BE20F72019C

Q34803707-612CE33C-F1E0-4A46-9D19-890523EA7A55

Q34803707-72E8D96F-A7B8-42B4-AAB1-470D595BECA0

Q34803707-A325CF72-F6CA-4F5A-A99F-99D2E422A72C

Q34803707-AF2FBF39-504E-4E59-B1B4-5FA194C65066

Q34803707-B1234E8B-E5FD-4EB6-A3AE-49257AC78A54

Q34803707-B2D9EB6C-2C5D-4B66-932C-5B86E5DE5DDD

P2860

Q34803707-01B3F39F-8F18-4200-B5CC-125C13F1AFD0

Q34803707-01FED505-BAD1-490D-9083-B386DA8CE57A

Q34803707-029BC7AF-05B0-490B-858F-BF70C742AAE6

Q34803707-030D374F-4584-42CE-82A3-7D1EB2178980

Q34803707-05C2DFCC-BB58-4C16-B207-3EABB73644F6

Q34803707-196D9478-EF53-43A1-9446-39C6CE38DE0D

Q34803707-20FDC0A5-F438-4C7C-82F9-4525BFB01B1E

Q34803707-2F52A959-BC8E-4D79-A584-A6D58BEA8826

Q34803707-342CF352-EB1B-4EBC-B0B9-F8597069D7CC

Q34803707-37329B42-D2CE-47B3-A376-379E0B181394

P304

Q34803707-E2E32EBA-F40F-4F35-B66B-15A5C329AC93

P31

Q34803707-557C3290-44CE-4157-A885-0F3873F0124E

P356

Q34803707-DAF30860-FB5F-427B-8B02-9D0F3E1CABED

P407

Q34803707-0D831294-EFC8-4E1B-B6D6-062131C47EE5

P433

Q34803707-32FC5884-4EE4-409F-9447-DB8BA1B56F5D

P478

Q34803707-77D3D8F0-AE33-41D8-9E38-E9ED6EF8D53A

P577

Q34803707-7DF1FD10-A546-41FD-8718-7B7F00BB581D

P5875

Q34803707-EEF0F74A-CC8B-4B6B-B872-5661050B3783

P698

Q34803707-FE168DD1-9D1F-4DF9-80E9-063BE3CFBF2D

P921

Q34803707-DA3B00B1-1A50-4A46-8174-4C2756AD5762

Q34803707-F3E88F4A-554F-4DB0-884E-8FD17BF8BD4C

P932

Q34803707-80ED37D9-77BD-4130-8BCE-4CC525C0055D

P356

1078-0432.CCR-13-0955

P1433

Clinical Cancer Research

P1476

Generation of tumor antigen-sp ...... mplications for immunotherapy.

@en

P2093

A John Barrett

http://www.w3.org/2001/XMLSchema#string

Ann M Leen

http://www.w3.org/2001/XMLSchema#string

Catherine M Bollard

http://www.w3.org/2001/XMLSchema#string

Gerrit Weber

http://www.w3.org/2001/XMLSchema#string

Ignazio Caruana

http://www.w3.org/2001/XMLSchema#string

Karen R Rabin

http://www.w3.org/2001/XMLSchema#string

Rayne H Rouce

http://www.w3.org/2001/XMLSchema#string

Ulrike Gerdemann

http://www.w3.org/2001/XMLSchema#string

P2860

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity

PRAME gene expression in childhood acute lymphoblastic leukemia

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemot

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.

P304

5079-5091

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-0955

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

248383736

http://www.w3.org/2001/XMLSchema#string

P698

23838315

http://www.w3.org/2001/XMLSchema#string

P921

P932

3778051

http://www.w3.org/2001/XMLSchema#string